[1]甘红婉,肖德俊,曾 瑜,等.奥洛他定联合匹多莫德治疗慢性荨麻疹的疗效及对外周血淋巴细胞亚群影响[J].医学信息,2018,31(21):144-146.[doi:10.3969/j.issn.1006-1959.2018.21.041]
　GAN Hong-wan,XIAO De-jun,ZENG Yu,et al.Efficacy of Olopatadine Combined with Pidotimod in the Treatment of Chronic Urticaria and Its Effect on Peripheral Blood Lymphocyte Subsets[J].Journal of Medical Information,2018,31(21):144-146.[doi:10.3969/j.issn.1006-1959.2018.21.041]
点击复制

奥洛他定联合匹多莫德治疗慢性荨麻疹的疗效及对外周血淋巴细胞亚群影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年21期
页码:
144-146
栏目:
药物与临床
出版日期:
2018-11-01

文章信息/Info

Title:
Efficacy of Olopatadine Combined with Pidotimod in the Treatment of Chronic Urticaria and Its Effect on Peripheral Blood Lymphocyte Subsets
文章编号:
1006-1959（2018）21-0144-03
作者:
甘红婉1; 肖德俊2; 曾 瑜1; 杨 萍1; 钟 雨1
赣州市人民医院皮肤科1，检验科2，江西 赣州 341000
Author(s):
GAN Hong-wan1; XIAO De-jun2; ZENG Yu1; YANG Ping1; ZHONG Yu1
Department of Dermatology1,Department of Laboratory2,Ganzhou People's Hospital,Ganzhou 341000, Jiangxi,China
关键词:
奥洛他定; 匹多莫德; 慢性荨麻疹; 淋巴细胞亚群
Keywords:
Olopatadine; Pidotimod; Chronic urticaria; Lymphocyte subsets
分类号:
R758.24
DOI:
10.3969/j.issn.1006-1959.2018.21.041
文献标志码:
A
摘要:
目的 观察奥洛他定联合匹多莫德口服对慢性荨麻疹患者临床疗效及外周血淋巴细胞亚群影响。方法 选择我院皮肤科门诊2018年1月~7月收治的56例慢性荨麻疹患者，按随机数表法均为A组和B组，各28例。A组单用奥洛他定治疗，B组采取奥洛他定联合匹多莫德治疗，另设健康对照组20例，治疗4周后比较A、B两组患者临床疗效，三组外周血T、B、NK淋巴细胞比例变化及不良反应发生率。结果 A组治疗总效率为57.14%，低于B组的92.85%，差异有统计学意义（P＜0.05）；A组治疗前后比较：CD3+、CD3+CD4+、CD19+、CD16+56+水平变化无统计学意义（P＞0.05）；CD3+CD8+增高、CD3+CD4+/CD3+CD8+降低，差异有统计学意义（P＜0.05）；B组治疗前后比较：CD3+、CD19+水平变化无统计学意义（P＞0.05），CD3+CD8+增高，CD3+CD4+、CD3+CD4+/CD3+CD8+、CD16+56+降低，差异有统计学意义（P＜0.05）；治疗后，两组患者CD19+水平变化无统计学意义（P＞0.05），A组患者CD3+、CD3+CD8+水平低于B组，CD3+CD4+、CD3+CD4+/CD3+CD8+、CD16+56+水平高于B组，差异有统计学意义（P＜0.05）；治疗过程中A组1例患者出现嗜睡、B组出现2例，均可耐受。结论 奥洛他定联合匹多莫德能有效治疗慢性荨麻疹，改善患者外周血淋巴细胞亚群水平，提高患者自身免疫力，安全有效。
Abstract:
Objective To observe the clinical effect of Olopatadine combined with Pidotimod on chronic urticaria and the effect of peripheral blood lymphocyte subsets.Methods 56 patients with chronic urticaria were selected from January to July 2018 in our the department of dermatology of our hospital. According to the random number method, 28 cases in group A and 28 cases in group B were selected.Group A was treated with Olopatadine alone, group B with Olopatadine combined with Pidotimod, and control group with 20 healthy person.After 4 weeks of treatment, the clinical efficacy were compared among A and B, T, B, NK lymphocyte ratio and adverse reactions in three groups were compared.Results The total therapeutic efficiency in group A was 57.14%, which was lower than that in group B 92.85%,the difference was statistically significant(P<0.05).Before and after treatment, the levels of CD3+,CD3+CD4+,CD19+,CD16+56+ were not significantly changed in group A(P>0.05).CD3+CD8+ increased and CD3+CD4+/CD3+CD8+ decreased,the difference was statistically significant (P<0.05).In group B, there was no significant difference in CD3+ and CD19+ levels before and after treatment(P>0.05),CD3+CD8+ increased, CD3+CD4+，CD3+CD4+/CD3+CD8+,CD16+56+ significantly decreased,the difference was statistically significant(P<0.05).After treatment, there was no significant difference in the level of CD19+ between the two groups(P>0.05). The levels of CD3+ and CD3+ CD8+ were lower in group B than in group A.The levels of CD3+CD4+,CD3+CD4+/CD3+CD8+,CD16+56+ were significantly higher than those in group B,the difference was statistically significant(P<0.05).During the course of treatment, 1 patient in group A developed somnolence and 2 in group B, which could be tolerated.Conclusion Olopatadine combined with Pidotimod can effectively treat chronic urticaria, improve the level of lymphocyte subsets in peripheral blood of patients, improve the patients' own immunity, and be safe and effective.

参考文献/References:

[1]Marrouche N,Grattan C.Update and insights into treatment options for chronic spontaneous urticaria[J].Expert Rev Clin Immunol,2014,10(3):397-403. [2]Monroe E,Finn A,Petal P,et al.Efficacy and safety of desloratadine 5mg once daily in the treatment of chronic idiopathic urticaria: a double-blind,randomized,placebocontrolled trial[J].J Am Acad Dermatol,2003,48(4):535-541. [3]刘凤英,胡建锋,蒋彬.慢性荨麻疹患者T细胞亚群、白细胞介素、免疫球蛋白与补体的检测及临床意义[J].中国卫生检验杂志,2018,28(1):76-78. [4]Incorvaia C,Mauro M,Russello M,et al.Omalizumab, an anti-immunoglobulin E antibody:state of the art[J].Drug Des Devel Ther,2014,8(1):197-207. [5]Welz-Uubiak K,Reich A.Mediators of Pruritus in Lichen Planus[J].Autoimmune Dis,2013,27(9):1-4.

相似文献/References:

[1]宋燕飞.奥洛他定与枸地氯雷他定治疗慢性荨麻疹的临床疗效及对临床症状的影响[J].医学信息,2022,35(23):93.[doi:10.3969/j.issn.1006-1959.2022.23.016]
　SONG Yan-fei.The Clinical Efficacy of Olopatadine and Desloratadine Citrate Disodium in the Treatment of Chronic Urticaria and its Effect on Clinical Symptoms[J].Journal of Medical Information,2022,35(21):93.[doi:10.3969/j.issn.1006-1959.2022.23.016]

更新日期/Last Update: 2018-11-20